Overview
NVS market data
Price History
NVS price chart
Valuation & Profitability
- P/E (TTM)
- 21.95 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $7.15 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.18 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 3.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 22.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $95.83 – $131.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $227.4B · P/B 5.57 · P/S 4.94.
Company News
Novartis India Approves Termination Of Distribution Agreement With Dr. Reddy’s Laboratories; Termination Agreement With Dr. Reddy’s Effective September 30, 2026; To Re-Buy Exclusivity And Market Access For Products After DRL Agreement TerminationBenzinga · Aug 7, 2026, 3:36 PM
Precision Medicine Collaboration and Licensing Deals 2019-2026 | Gain Access to Over 1,350 Deals and Benchmark with ConfidenceGlobenewswire Inc · Aug 7, 2026, 11:00 AM
MHRA Approves Remibrutinib For Adults With Chronic Spontaneous UrticariaBenzinga · Aug 6, 2026, 3:11 PM
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobenewswire Inc · Aug 5, 2026, 9:15 PM
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' PluvictoBenzinga · Aug 3, 2026, 4:56 PM
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are UnderratingThe Motley Fool · Jul 22, 2026, 11:00 AM
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035Globenewswire Inc · Jul 22, 2026, 11:00 AM
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in USBenzinga · Jul 22, 2026, 2:13 AM
Novartis Q2 2026 Earnings Call TranscriptBenzinga · Jul 21, 2026, 1:45 PM
Novartis Silences Generic Fears With Blowout Quarter, Packed PipelineBenzinga · Jul 21, 2026, 12:21 PM